UnitedHealthcare · Belimumab · US health-plan appeal rights

Belimumab denied as duplicate or overlapping therapy by UnitedHealthcare?

Q: How long do I have to appeal a UnitedHealthcare Belimumab denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-09

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What UnitedHealthcare typically requires

Adult or pediatric (≥5 yr) with SLE meeting EULAR/ACR 2019 criteria, autoantibody-positive (ANA ≥1:80 or anti-dsDNA positive), receiving standard therapy (HCQ + GC ± ISD). For LN indication: biopsy-proven ISN/RPS class III, IV, or V (or mixed) with active disease (UPCR ≥1 g/g) on background MMF or CYC. IV 10 mg/kg q4wk (after wk 0/2/4 loading) or SC 200 mg weekly. Reauth at 6 mo with SLEDAI-2K reduction, GC taper, or PERR (LN).

Source policy: OptumRx / UHC Benlysta (Belimumab) PA Criteria for SLE and Lupus Nephritis

What works in the appeal

BLISS-LN NEJM 2020 enrolled patients ON background MMF or CYC concurrently — belimumab is ADD-ON to standard therapy, not post-sequential-failure. PERR 43% vs 32% (OR 1.55, p=0.031); CRR 30% vs 20%. KDIGO 2024 rec 1.2.1 + EULAR 2025 explicitly endorse MMF + belimumab as initial regimen for active proliferative LN. EULAR/ACR 2019 entry is ANA ≥1:80 — anti-dsDNA negativity does not exclude classification (additive scoring across 7 clinical + 3 immunological domains). Cite SLEDAI-2K + organ damage (SDI) to demonstrate active disease.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other UnitedHealthcare appeals

Other denial reasons for UnitedHealthcare Belimumab

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-09. Editorial standards: denialhelp.com/authors.